MedTrace Logo

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2021-01-06

Study results available
· View outcomes & findings →

Summary

The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.

Conditions

Interventions

DRUG

1 drop of 0.375% SYL040012 (bamosiran)

DRUG

1 drop of 0.750% SYL040012 (bamosiran)

DRUG

1 drop of 1.125% SYL040012 (bamosiran)

DRUG

1 drop of 1.5% SYL040012 (bamosiran)

DRUG

1 drop of 0.5 % timolol maleate

Sponsors & Collaborators

  • Sylentis, S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-08-31
Completion
2016-01-31

Countries

  • United States
  • Estonia
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02250612 on ClinicalTrials.gov